Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ATP7B	540	CARBOPLATIN	CHEMBL1351		NCI	15213293
ATP7B	540	OXALIPLATIN	CHEMBL414804		NCI	15213293

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ATP7B	rs9535828	A	Platinum compounds	efficacy	yes	using a dominant model the authors conclude that the A allele at rs9535828 is associated with increased response ("responders") to platinum therapy.	Allele A is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele G.	24852429	1184754406
ATP7B	rs1061472	T	Platinum compounds	efficacy	no	rs1061472 was not significantly associated with resistance ("non-responders") to platinum therapy. The authors tested a recessive, dominant and additive model. None were significant.	Allele T is not associated with resistance to Platinum compounds in people with Lung Neoplasms as compared to allele C.	24852429	1184754410
ATP7B	rs7999812	C	Platinum compounds	efficacy	no	rs7999812 was not significantly associated with resistance ("non-responders") to platinum therapy. The authors tested a recessive, dominant and additive model. None were significant.	Allele C is not associated with resistance to Platinum compounds in people with Lung Neoplasms as compared to allele A.	24852429	1184754414
ATP7B	rs9535826	G	Platinum compounds	efficacy	yes	using a dominant model the authors conclude that the G allele at rs9535826 is associated with increased response ("responders") to platinum therapy.	Allele G is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele T.	24852429	1184754389